The Washington State Department of Health (DOH) will host a live webinar February 18 to discuss the phasing and rollout of COVID-19 vaccines in our state. The webinar, " Understanding WA's COVID-19 Vaccine Phases," will feature Umair A. Shah, MD, MPH, Secretary of Health, SheAnne Allen, COVID-19 vaccine director, and Dr. Christopher Chen, medical director - Medicaid, Washington Health Care Authority.
The Washington State Department of Health will be holding a public webinar, Thursday February 18th, from 5-6PM. The purpose, according to WSDOH: "...to discuss the phasing and rollout of COVID-19 vaccines in our state. The webinar, "Understanding WA's COVID-19 Vaccine Phases," will feature Umair A.
Provention Bio is making its way into China with a new deal announced Wednesday. The Red Bank, NJ-based biotech has agreed to a deal with a subsidiary of Huadong Medicine to work on PRV-3279, a bispecific antibody-based molecule targeting CD32B and CD79B, in China, Hong Kong, Macau and Taiwan. Provention
Ozette, a Seattle, Washington-based life sciences startup, today announced that it raised $6 million in seed funding from Madrona Venture Group and the Allen Institute for AI (AI2). Ozette, a collaboration between AI2 and the Fred Hutchinson Cancer Research Center, says it'll use the seed funding, which brings its total raised to date $12 million, to accelerate breakthroughs in tracking disease.
New funding: Ozette, a biotech company that last year spun out of the Fred Hutchinson Cancer Research Center and was incubated at the Allen Institute for Artificial Intelligence (AI2), has raised a $6 million seed round. The Seattle-based company has eight employees with plans to double that number in the next few months with the fresh cash.
Asian Americans report a lower rate of healthcare utilization and awareness of hypertension compared to other racial/ethnic groups. Additionally, a high proportion of Asian Americans, 62%, report having limited English proficiency (LEP). Previous literature reported that Asian Americans with LEP have trouble receiving specialized and quality healthcare.
According to the American Community Survey, 3% of women aged 16 years and older, have a visual disability. The CDC defines visual impairment as legal blindness or low visual acuity (20/200 or worse) in at least one eye during the use of corrective lenses.
Adoptive transfer of engineered T cells is a strategy for producing potent anti-tumor immune responses in cancer patients. These therapies have produced dramatic clinical outcomes, particularly against blood-borne cancers. Applications of T-cell therapy against solid tumors, however, have faced several major hurdles, including poor trafficking of T cells to solid tumor sites, and suppression of therapeutic T-cell responses within the solid tumor microenvironment (TME).
The story of cancer is, largely, one of broken genes. The valiant tumor suppressor, defender of cellular integrity, maimed and enfeebled. The conniving oncogene, hyper-activated, allowed to run wild and sow chaos within the cell. These genes are many, and they act on an array of cellular processes. Cell growth.
Kaposi sarcoma-associated herpesvirus (KSHV), also known as Human Herpesvirus 8, is a gamma herpesvirus that is often harmless, but causes a cancer called Kaposi sarcoma (KS) in a subset of infections. People infected with HIV, especially those who are not treated with antiretroviral therapy, are disproportionately affected by KS.
Effective antibody responses against HIV are rare both during natural infection and after vaccination. As a result, many research groups have focused their efforts on identifying and characterizing rare but potent antibodies in order to design a vaccine that would stimulate their production.
Over time skin cells accumulate mutations with the potential to give rise to cancer, yet often mutant clones remain contained in clusters and do not spread. Researchers in the Beronja lab (Human Biology Division) study the molecular and cellular mechanisms that regulate epithelial growth in development and cancer.
Gene therapy may offer potential cures, but its promise comes with a price. Some experimental approaches require a multi-step process to prepare stem cells for the procedure-a burden to a patient and to the healthcare system, according to Paula Soteropoulos, executive chair of startup Ensoma. Soteropoulos's company is proposing an alternative.
Nature delivered a rare treat to thousands of people across the Puget Sound region Saturday, sending them outside to cast aside pandemic gloom to play in a foot of snow. At least that's one view. The other can be seen from behind a snow shovel, while assessing the damage of a fender-bender, or trapped on a Metro bus going nowhere.
(UroToday.com) In this panel discussion, the presenters answered questions from the audience on the prior session, which are summarized here. Question: In ovarian cancer, perhaps one of the most effective means to predict response to PARPi is prior response to platinum, irrespective of HRD status. Thoughts for prostate cancer?
Over the last decade, Hans-Peter Kiem, the Fred Hutch stem cell biologist, and 5AM Ventures chief Kush Parmar founded a slate of prominent biotechs, including Vor and Homology Medicines. But whenever the two spoke, there was one idea Kiem couldn't stop pitching. Kiem wanted to build a gene therapy biotech
The overall response rate (ORR) of ruxolitinib (Jakafi) was significantly higher than best available therapy (BAT), 49.7% versus 25.6% (odds ratio [OR], 2.99; 95% CI, 0.86-4.80; P < .0001), respectively, in adolescent and adult patients with chronic graft-versus-host disease (cGVHD), according to findings presented by Stephanie J.
Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.
With the backing of Paul Allen and Jeff Bezos, among others, Nautilus Biotechnology is setting sail for Nasdaq, inking a deal with one of Perceptive's blank-check companies to unlock the mysteries of the human proteome. The Seattle-based biotech will reverse merge with Arya Sciences Acquisition Corp III, which penciled in
New spinout: Boston-based biotech startup Ensoma launched Thursday and announced a $70 million Series A funding round. The company is built on technology developed over two decades by Seattle researchers Dr. Hans-Peter Kiem of the Fred Hutchinson Cancer Research Center and Dr. André Lieber of the University of Washington School of Medicine.